BRAINCURES

Precision Medicine Based on Biological Intelligence-Alzheimer's Disease Case Study. Highlights: BRAINCURES Discovery Engine (BDE) associated early- to late-long-term potentiation (LTP) targets, compounds and biomarkers prioritize known and novel opportunities for Alzheimer’s disease  Other applications of the BDE Platform 1) BDE100-prioritization of 20 of 55 Alzheimer’s investigational drugs based on 98 shared signatures within the BDE-L1000 datasets 2) 37 BDE-Hubs prioritize 83 of 199 investigational Alzheimer’s compounds. 4 BDE-Masters prioritize 9 of 199 AD-linked compounds 3) Prioritization of 4 BDE-Targets, 6 plasticity genes, 18 hubs within Genomics England’s 42 gene early dementia biomarker panel

Cdkl5 + long term potentiation = 7 publications. BRAINCURES Discovery Engine (BDE) -Targets and -Compounds prioritizes 292 (41%) and 81 (11%) Cdkl5 publications, respectively.

It’s World Mental Health Day-support BRAINCURES’ quest to help biotech and pharma companies deliver cures for brain diseases at JustGiving https://lnkd.in/d6uUgvtg

Biological Intelligence: A Molecular Map Approach to Preclinical and Clinical Success. See 1) Move over AI? Here comes biological intelligence https://lnkd.in/gfjHaFuC;  2) BRAINCURES’ biology-driven approach to precision medicine https://lnkd.in/gub785Nf 3) AI Joins Forces with Biology to Tackle Neuro Diseases https://lnkd.in/exWzvvEq

Flash 3-minute presentation at ELRIG UK Drug Discovery 2024 on Thursday 3rd October, 12.50 to 14.00 in the Learning Zone. See you at ExCeL in London

21 September is World Alzheimer's Day during #WorldAlzheimersMonth. Here are some highlights from the 176-page Alzheimer's Disease International World Alzheimer Report 2024: Global changes in attitudes to dementia https://lnkd.in/gmNHrZN8. The report explores attitudes toward #dementia, examining how the condition is perceived and understood by society and the stigma that still surrounds the condition, underpinned by a global survey of more than 40,000 individuals across 166 countries and territories, and 24 expert essays. #WorldAlzheimersDay #TimeToActOnDementia #TimeToActOnAlzheimers

Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable by Najat Khan, Thomas Senderovitz, James Weatherall, Janice Branson, Benedikt Egersdoerfer, Eric Genevois-Marlin, Sai Jasti, Mustaqhusain Kazi, Ranjit Kumble, Patrick Loerch, Justine Rochon, Venkat Sethuraman, Matt Studney, Xiaoying Wu, Ryan Copping, Priya Chandran, Madura Jayatunga, Dhruv Jayanth & Christoph Meier. Paywall: https://lnkd.in/eRhsJt_d. Free open access to the publication at Boston Consulting Group (BCG)'s site https://lnkd.in/g_QJm8gT

Depressive disorders: Treatment failures and poor prognosis over the last 50 years by Tom Blackburn, Founder and CEO TPBIOVENTURES UK LIMITED https://lnkd.in/d3TwizV4. Highlights: 1) A move in the right direction with a shift to biologically based diagnosis was initiated in 2008 by the NIMH as part of a long-term strategic initiative with their Research Domain Criteria Project (RDoc). Thomas Insel MD in proposing the NIMH's reorientation away from DSM categories stated, “We cannot succeed if we use DSM categories as the gold standard.” 2) The longest-standing theory of depression is based on monoamine dysfunction and drugs acting on monoamine neurotransmission which has dominated the treatment of depression for over 50 years, albeit much maligned in recent times as a too simplistic and may have misguided our understanding of the complexity of the disorder (8,32) 3) The impact of genetics on mental disorders over the last few decades have been disappointing, despite the enthusiasm for new era of personalized medicine and an individual's genome 4) The “Holy Grail” of current treatment strategies is to develop antidepressants with a fast onset of action 5) Although, blood tests remain elusive, advances are being made, for example, elevated morning cortisol is a stratified population-level biomarker for MDD in boys with high depressive symptoms along with 26 candidate biomarkers and compared their expression in human subjects with and without early onset MDD (95) 6) Several pharmaceutical companies still continue to bet on the tried and tested monoamine approach and various augmentation strategies (109), the most recent monoamine entrants in the US depression market being duloxetine (2004), agomelatine (2009), vortioxetine (2013)

Resources to mark World Brain Day 2024 #WorldBrainDay: 1) Trillion-dollar brain drain by Kerri Smith https://lnkd.in/dBd_8xqj 2) Novartis to shut brain research facility by Alison Abbott https://lnkd.in/dFVr42uW 3) Brain in Box by Mitch Waldrop https://lnkd.in/d7bT-xNM 4) Pharma Ins and Outs Neuroscience https://lnkd.in/e9Hwyz8b 5) Neuroscience Drug Pipeline Tracker https://lnkd.in/et9r7Ab3

Executive summary of how the biological intelligence powered BRAINCURES Discovery Engine (BDE) can advance biomarker- and biology driven treatments for Alzheimer's disease. Read more about the approach here https://lnkd.in/dgxgAAX